FDA approves Replimune melanoma treatment after two prior rejections

HEALTH: STAT+ (FDA)

The FDA approved Replimune’s treatment for advanced melanoma after two prior rejections. This resolves a critical barrier for patients with this aggressive cancer type who previously lacked access to this therapy. For melanoma patients in advanced stages, this approval means a new option becomes available where it was previously denied. The move directly addresses a need for effective, accessible cancer care that had been stalled by regulatory hurdles. Details remain with the source, as the original reporting is unreachable.

Source: STAT